Showing results (101-110 of 252) with videos related to

Sort By:
Pageof 26
Leukemia Research|May 19, 2017
Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphomaMarc Sorigue, Juan-Manuel Sancho, Alberto Pineda, et al.
Cancer|April 24, 2019
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA GroupJosep-Maria Ribera, Olga García, María-José Moreno, et al.
Clinical Case Reports|May 14, 2023
HHV8 and EBV-negative primary effusion-based lymphoma: A case report of a new provisional entity and review of literatureMarta Canelo-Vilaseca, Gustavo Tapia, Elisa Orna, et al.
Medicina Clinica|December 3, 2020
Low doses of gemtuzumab ozogamicin in adults diagnosed with acute myeloid leukaemiaMarta Peña Domingo, Susana Vives Polo, Ana Garrido Díaz, et al.
International Journal of Hematology|May 8, 2007
Outcome and prognostic factors in patients with hematologic malignancies admitted to the intensive care unit: a single-center experienceChristelle Ferrà, Pilar Marcos, Maite Misis, et al.
AIDS (London, England)|March 3, 2015
HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy eraMaria Joao Baptista, Olga Garcia, Mireia Morgades, et al.
Human Pathology|May 13, 2004
Oral solid form of primary effusion lymphoma mimicking plasmablastic lymphomaJosé-Luis Mate, José-Tomás Navarro, Aurelio Ariza, et al.
Cancer Medicine|February 6, 2020
A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trialJosep-Maria Ribera, Mireia Morgades, Pau Montesinos, et al.
European Journal of Haematology|December 31, 2015
Highly variable mutational profile of ASXL1 in myelofibrosisMarc Sorigué, Josep-Maria Ribera, Olga García, et al.
European Journal of Haematology|December 27, 2019
Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemiaNicola Gökbuget, Hervé Dombret, Sebastian Giebel, et al.
Pageof 26